Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | RAD52 | P43351 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.51 |
| ▸ | LPL | P06858 | 9/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | F11 | P03951 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19491333 | 0.90 | GAA (0.47) | GAARAD52MAPTKDM4EGFER | |
| SCHEMBL14852465 | 0.88 | DRD2 (0.54) | GAARAD52MAPTKDM4EGFER | |
| SCHEMBL19465603 | 0.87 | LPL (0.43) | GAARAD52MAPTKDM4EGFER | |
| SCHEMBL21296522 | 0.86 | KDM4E (0.51) | GAAKDM4ELPLLIPGSIGMAR1 | |
| SCHEMBL24506432 | 0.84 | KDM4E (0.41) | GAARAD52MAPTKDM4EGFER | |
| SCHEMBL29088143 | 0.84 | LPL (0.41) | GAARAD52MAPTKDM4EGFER | |
| SCHEMBL586151 | 0.84 | LPL (0.41) | GAAMAPTKDM4ELPLLIPG | |
| SCHEMBL14852301 | 0.84 | KDM4E (0.59) | GAAKDM4ELPLLIPGLMNA | |
| SCHEMBL15168853 | 0.83 | LPL (0.41) | GAARAD52MAPTKDM4EGFER | |
| SCHEMBL17289947 | 0.83 | LPL (0.44) | MAPTKDM4EGFERLPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595265-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2026-04-07 | — | — | US | disclosed |
| US-12534463-B2 | Substituted tricyclic compounds as FGFR inhibitors | INCYTE CORPORATION (US) | 2026-01-27 | — | — | US | disclosed |
| US-12516059-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250057852-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2025-02-20 | — | — | US | disclosed |
| US-12209091-B2 | Isoindolinone derivatives as selective allosteric inhibitors of Egfr mutant cancers | HOFFMANN-LA ROCHE INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240425479-A1 | HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-12-26 | — | — | US | disclosed |
| US-20240383889-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-11-21 | — | — | US | disclosed |
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-10-17 | — | — | US | disclosed |
| US-12083124-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240246974-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | INCYTE CORPORATION | 2024-07-25 | — | — | US | disclosed |
| US-8481525-B2 | Kinase inhibitors and method of treating cancer with same | UNIVERSITY OF HEALTH NETWORK (CA) | 2013-07-09 | — | — | US | disclosed |
| WO-2013051672-A1 | MEDICINAL AGENT COMPRISING THIAZOLIDINE DERIVATIVE OR SALT THEREOF AS ACTIVE INGREDIENT | 株式会社ヤクルト本社 (JP) | 2013-04-11 | — | — | WO | disclosed |
| US-20120264800-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORKS (CA) | 2012-10-18 | — | — | US | disclosed |
| US-8263596-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2012-09-11 | — | — | US | disclosed |
| US-20120149686-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORKS (CA) | 2012-06-14 | — | — | US | disclosed |
| EP-2417127-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | University Health Network (CA) | 2012-02-15 | — | — | EP | disclosed |
| US-20110263598-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORKS (CA) | 2011-10-27 | — | — | US | disclosed |
| WO-2010115279-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2010-10-14 | — | — | WO | disclosed |
| US-20060004051-A1 | Compounds | DODIC NERINA | 2006-01-05 | — | — | US | disclosed |
| US-20050245520-A1 | 2-Phenylpyridin-4-yl derivatives as alk5 inhibitors | DODIC NERINA | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245520-A1 | 2-Phenylpyridin-4-yl derivatives as alk5 inhibitors | SMAD2, SMAD3, ALK | GAA 1784/4885RAD52 3885/4885MAPT 1496/4885 |
| US-20240383889-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | GAA 762/4885RAD52 3435/4885MAPT 4343/4885 |
| US-12083124-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | GAA 1045/4885RAD52 4028/4885MAPT 4204/4885 |
| US-12534463-B2 | Substituted tricyclic compounds as FGFR inhibitors | FGFR3, FGFR1, FGFR4 | GAA 2000/4885RAD52 1526/4885MAPT 2782/4885 |
| US-20120264800-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | GAA 1351/4885RAD52 3638/4885MAPT 2002/4885 |
| US-12209091-B2 | Isoindolinone derivatives as selective allosteric inhibitors of Egfr mutant cancers | EGFR, ERBB2, ERBB3 | GAA 3754/4885RAD52 2962/4885MAPT 2305/4885 |
| US-20120149686-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | MAP3K5, MAP3K6, MAP3K1 | GAA 1213/4885RAD52 3486/4885MAPT 1467/4885 |
| US-20240246974-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | FGFR3, FGFR1, FGFR2 | GAA 205/4885RAD52 3897/4885MAPT 3136/4885 |
| US-20250057852-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | GAA 1045/4885RAD52 4028/4885MAPT 4204/4885 |
| US-20110263598-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | GAA 1351/4885RAD52 3638/4885MAPT 2002/4885 |
| US-12595265-B2 | Inhibitors of activin receptor-like kinase | ACVR1, ACVRL1, ACVR2A | GAA 3452/4885RAD52 3392/4885MAPT 4748/4885 |
| US-20060004051-A1 | Compounds | SMAD3, SMAD2, TGFBR1 | GAA 2499/4885RAD52 3874/4885MAPT 697/4885 |
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | CMPK1, WNK1, AAK1 | GAA 3039/4885RAD52 4353/4885MAPT 3643/4885 |
| US-20240425479-A1 | HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | DCK, CMPK1, WNK1 | GAA 2284/4885RAD52 3793/4885MAPT 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.